JP2020514361A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514361A5 JP2020514361A5 JP2019550659A JP2019550659A JP2020514361A5 JP 2020514361 A5 JP2020514361 A5 JP 2020514361A5 JP 2019550659 A JP2019550659 A JP 2019550659A JP 2019550659 A JP2019550659 A JP 2019550659A JP 2020514361 A5 JP2020514361 A5 JP 2020514361A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- fibrosis
- compound according
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 14
- 206010016654 Fibrosis Diseases 0.000 claims 10
- 230000004761 fibrosis Effects 0.000 claims 10
- 208000011580 syndromic disease Diseases 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 7
- 125000001931 aliphatic group Chemical group 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 230000001363 autoimmune Effects 0.000 claims 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 239000011593 sulfur Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 206010052779 Transplant rejections Diseases 0.000 claims 5
- 230000001154 acute effect Effects 0.000 claims 5
- 230000000735 allogeneic effect Effects 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 208000032612 Glial tumor Diseases 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 206010040070 Septic Shock Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 208000034189 Sclerosis Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 2
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 2
- 201000004458 Myoma Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 201000002661 Spondylitis Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000036244 malformation Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 206010034674 peritonitis Diseases 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 231100000241 scar Toxicity 0.000 claims 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 2
- 230000001568 sexual effect Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 230000001256 tonic effect Effects 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 206010001324 Adrenal atrophy Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010004664 Biliary fibrosis Diseases 0.000 claims 1
- 201000003274 CINCA syndrome Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 241000324343 Causa Species 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000014311 Cushing syndrome Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012426 Dermal cyst Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 206010053776 Eosinophilic cellulitis Diseases 0.000 claims 1
- 241000483002 Euproctis similis Species 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010058490 Hyperoxia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 206010054107 Nodule Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010058461 Orchitis noninfective Diseases 0.000 claims 1
- 206010033165 Ovarian failure Diseases 0.000 claims 1
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 208000037581 Persistent Infection Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 claims 1
- 206010039580 Scar Diseases 0.000 claims 1
- 206010048908 Seasonal allergy Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 208000008526 Wells syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 201000004339 autoimmune neuropathy Diseases 0.000 claims 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 claims 1
- 229950010333 exalamide Drugs 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000000222 hyperoxic effect Effects 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000006512 mast cell neoplasm Diseases 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000004535 ovarian dysfunction Diseases 0.000 claims 1
- 231100000539 ovarian failure Toxicity 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022200392A JP2023051962A (ja) | 2017-03-16 | 2022-12-15 | ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472027P | 2017-03-16 | 2017-03-16 | |
| US62/472,027 | 2017-03-16 | ||
| PCT/US2018/022548 WO2018170204A1 (en) | 2017-03-16 | 2018-03-15 | 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022200392A Division JP2023051962A (ja) | 2017-03-16 | 2022-12-15 | ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514361A JP2020514361A (ja) | 2020-05-21 |
| JP2020514361A5 true JP2020514361A5 (https=) | 2021-04-22 |
Family
ID=63522566
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550659A Pending JP2020514361A (ja) | 2017-03-16 | 2018-03-15 | ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用 |
| JP2022200392A Pending JP2023051962A (ja) | 2017-03-16 | 2022-12-15 | ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022200392A Pending JP2023051962A (ja) | 2017-03-16 | 2022-12-15 | ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11098057B2 (https=) |
| EP (1) | EP3596084A4 (https=) |
| JP (2) | JP2020514361A (https=) |
| WO (1) | WO2018170204A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| US11098057B2 (en) | 2017-03-16 | 2021-08-24 | Celgene Car Llc | 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof |
| EP3596085A4 (en) | 2017-03-16 | 2020-11-25 | Celgene CAR LLC | DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES |
| WO2018170200A1 (en) * | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| WO2018170203A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| US10882867B2 (en) | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
| WO2020236636A1 (en) * | 2019-05-17 | 2020-11-26 | Celgene Car Llc | Methods of treating a mk2-mediated disorder |
| CN116670142A (zh) | 2021-02-01 | 2023-08-29 | 细胞基因公司 | Mk2抑制剂、其合成和其中间体 |
| WO2023025298A1 (zh) * | 2021-08-27 | 2023-03-02 | 瑞石生物医药有限公司 | 喹啉并呋喃衍生物及其用途 |
| JPWO2024048697A1 (https=) * | 2022-08-31 | 2024-03-07 | ||
| CN115925718A (zh) * | 2022-12-27 | 2023-04-07 | 瑞石生物医药有限公司 | 一种四环内酰胺衍生物及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| ZA200504898B (en) | 2002-12-20 | 2006-11-29 | Pharmacia Corp | Acyclic pyrazole compounds |
| US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| MX2009014247A (es) | 2007-07-16 | 2010-01-28 | Novartis Ag | Compuestos heterociclicos utiles como inhibidores de mk2. |
| JP2011501578A (ja) * | 2007-10-20 | 2011-01-06 | ペナンゴ，インコーポレイテッド | セキュア通信の信頼性を示すための方法及びシステム |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| WO2014011902A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CA2908098A1 (en) | 2013-03-15 | 2014-09-25 | Celgene Avilomics Research, Inc. | Mk2 inhibitors and uses thereof |
| RS62017B1 (sr) * | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| WO2018170203A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Mk2 inhibitors, synthesis thereof, and intermediates thereto |
| US11098057B2 (en) | 2017-03-16 | 2021-08-24 | Celgene Car Llc | 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof |
| WO2018170200A1 (en) | 2017-03-16 | 2018-09-20 | Celgene Car Llc | Heteroaryl compounds useful as mk2 inhibitors |
| US10882867B2 (en) | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
| EP3596085A4 (en) | 2017-03-16 | 2020-11-25 | Celgene CAR LLC | DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES |
-
2018
- 2018-03-15 US US16/494,722 patent/US11098057B2/en active Active
- 2018-03-15 WO PCT/US2018/022548 patent/WO2018170204A1/en not_active Ceased
- 2018-03-15 EP EP18766809.0A patent/EP3596084A4/en not_active Withdrawn
- 2018-03-15 JP JP2019550659A patent/JP2020514361A/ja active Pending
-
2022
- 2022-12-15 JP JP2022200392A patent/JP2023051962A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514361A5 (https=) | ||
| JP2020511468A5 (https=) | ||
| JP2020512315A5 (https=) | ||
| JP2020514360A5 (https=) | ||
| TWI847144B (zh) | 奧美卡替莫卡必爾的合成 | |
| JP2020523390A5 (https=) | ||
| JP2022531969A5 (https=) | ||
| JP7744024B2 (ja) | ５－フルオロニコチンアミド誘導体およびその使用 | |
| JP6830888B2 (ja) | Ｊａｋ阻害剤の硫酸水素塩の結晶形およびその製造方法 | |
| US8198276B2 (en) | Kinase inhibitor compounds | |
| CN105431436A (zh) | 吡咯并[2,3-d]嘧啶衍生物，它们的制备方法和它们作为激酶抑制剂的用途 | |
| JP2020528907A5 (https=) | ||
| JP2022531088A5 (https=) | ||
| JP2020517611A5 (https=) | ||
| CN101611015A (zh) | 用于治疗糖皮质激素受体所介导紊乱的吲唑基酯和吲唑基酰胺衍生物 | |
| TWI585087B (zh) | Novel tetrahydropyridine pyrimidine compounds or salts thereof | |
| US10800763B2 (en) | Polymorphic forms of Afatinib free base and Afatinib dimaleate | |
| JP2022533340A5 (https=) | ||
| WO2016078160A1 (zh) | 胞苷衍生物及其应用 | |
| CN109956906A (zh) | 一种噁拉戈利关键中间体的制备方法 | |
| JP2022521413A5 (https=) | ||
| JP2012517991A (ja) | ベンゾイルアミノヘテロシクリル化合物の製造方法 | |
| JP2020530497A (ja) | ３−（５−フルオロベンゾフラン−３−イル）−４−（５−メチル−５Ｈ−［１，３］ジオキソロ［４，５−ｆ］インドール−７−イル）ピロール−２，５−ジオンの固体形態 | |
| TWI805751B (zh) | 賽度替尼(cerdulatinib)之合成 | |
| CN107722007B (zh) | 阿哌沙班杂质的制备方法 |